Abstracts tagged "prevention"

Abstract Number: 2588 • ACR Convergence 2024
Examining the Influence of Socioeconomic Status on Osteoarthritis Prevalence and Risk Factors Among New York Residents
Titilayo Adeniran¹, David Cecil² and Ahinee Amamoo³, ¹Hospital for Special Surgery (HSS), New York, NY, ²Samford University, Birmingham, ³Samford University, Birmingham, AL
Background/Purpose: Osteoarthritis (OA) is a chronic, progressive condition affecting the musculoskeletal system, significantly impacting the quality of life and mobility of millions worldwide. It is…
Abstract Number: 0138 • ACR Convergence 2024
SARS-CoV-2 Vaccine Acceptance, Hesitancy and Uptake in a Cohort of Patients with Inflammatory Rheumatic Diseases (IRD)
iulia roman¹, Xenofon Baraliakos², Uta Kiltz³, Juergen Braun⁴ and Ioana Andreica⁵, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: Vaccine acceptance is important to achieve high vaccination coverage and possibly herd immunity. Related to the evolution of the SARS-CoV-2 pandemic with its socio-political…
Abstract Number: 0995 • ACR Convergence 2024
What Is the Carbon Footprint of Adalimumab Originator and Its Various Biosimilar Drugs?
Ines Moninot¹, ROLAND CHAPURLAT², Elodie FEURER¹, Pierre-Jean Cottinet³, Minh-Quyen Le³ and Aurélie Fontana¹, ¹Hospices Civils Lyon, Lyon, France, ²INSERM 1033, LYON, France, ³INSA Lyon, Lyon, France
Background/Purpose: In developed countries, the impact of healthcare systems on the environment is sizeable (roughly 8% of the carbon footprint). So, it is essential to…
Abstract Number: 2612 • ACR Convergence 2024
Two-Week Methotrexate Discontinuation in Autoimmune Rheumatic Diseases Patients Vaccinated with Recombinant Herpes Zoster Vaccine: An Interim Analysis of a Prospective Randomized Phase 4 Study
Ana Cristina Medeiros-Ribeiro¹, Joao de Oliveira², Nadia Aikawa³, Sandra Pasoto², Leonard Kupa², Carla Goncalves Schahin Saad⁴, Luciana Parente², ANA PAULA ASSAD², Eduardo Borba², Emily Figueiredo Neves Yuki², Andrea Shimabuco⁴, Karina Bonfiglioli², Diogo Domiciano², Percival Sampaio-Barros⁴, Andre Franco², Julio Moraes⁵, Murillo Dorio², Claudia Goldenstein-Schainberg², Henrique Carriço Da Silva², Lucas Guimarães², Fernanda Chaer⁶, Caio Laguna Reis de Carvalho², Henrique Dalmolin², Clovis Silva⁷ and Eloisa Bonfa², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, ²Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, ³Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, ⁴Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Santos, Brazil, ⁷Rheumatology Division and Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil
Background/Purpose: Temporary methotrexate (MTX) discontinuation may enhance vaccine immune response, but there are no data for the recombinant zoster vaccine (RZV). This study assessed if…
Abstract Number: 0156 • ACR Convergence 2024
Psoriasis and Psoriatic Arthritis Are Independent Risk Factors for Non-Fatal Cardiovascular Admissions in Transition-Age Young Adults
Anurag Goel¹, Joshua Tanzer² and Vinit Gilvaz³, ¹The Warren Alpert Medical School of Brown University, Providence, RI, ²Lifespan Biostatistics, Epidemiology, Research Design, and Informatics Core, Providence, RI, ³The Warren Alpert Medical School of Brown University, East Providence, RI
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated…
Abstract Number: 1066 • ACR Convergence 2024
Development of a Pharmacy-Led Intervention to Improve Osteoporosis Screening in VA Community-Based Outpatient Clinics
Krista Topalsky¹, Lee Arphai², Mary Ellen Amos², Amanda Mertz², Christopher Blum³, Timothy Godbey², Lori Leonard², Maya Mattar⁴, Elizabeth Cable² and Robert Wenzell², ¹University Hospitals/ Case Western Reserve University, Shaker Heights, OH, ²Cleveland VA Medical Center, Cleveland, OH, ³Cleveland VA Medical Center, Cleveland, ⁴Louis Stokes VA medical Center, Mayfield Heights, OH
Background/Purpose: Osteoporosis is a major public health concern in the United States, leading to significant morbidity, mortality, and increased economic burden. Fractures are projected to…
Abstract Number: 2672 • ACR Convergence 2024
Prevention of the Development of Rheumatoid Arthritis by a 1-year Course of Methotrexate in ACPA-negative Arthralgia Patients at Increased Risk for Rheumatoid Arthritis: 4 Year Results of the TREAT EARLIER Trial
Quirine Dumoulin¹, Doortje Krijbolder², Karen Visser³, Leroy Lard⁴ and Annette van der Helm-van Mil⁵, ¹Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Haga Hospital The Hague, Amsterdam, Netherlands, ⁴Haaglanden Medical Center The Hague, Leidschendam, Netherlands, ⁵LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Currently, prevention possibilities of developing ACPA-negative rheumatoid arthritis (RA) are unknown. Studying this is challenging because many ACPA-negative at-risk individuals have low risk of…
Abstract Number: 0207 • ACR Convergence 2024
Investigation of Delays in Cancer Screening in RA
Rebecca Brooks¹, Cassondra Hulshizer², Andrew C. Hanson³, Vanessa Kronzer¹, John Davis¹, Elena Myasoedova¹ and Cynthia Crowson¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Utica, MN, ³Mayo Clinic, Rochester
Background/Purpose: Recent studies have shown that RA patients have increased mortality due to cancer. Despite the increased mortality, few studies have investigated the completion of…
Abstract Number: 1075 • ACR Convergence 2024
Optimizing Herpes Zoster Vaccination in Rheumatoid Arthritis Patients Ages 18-49 Years: A Quality Improvement Approach
Akhil Sood¹, Pegah Jahangiri¹, Christy Bill² and Janice Lin¹, ¹Stanford University, Palo Alto, CA, ²Stanford Health Care, Palo Alto, CA
Background/Purpose: Patients with rheumatoid arthritis are at increased risk for Herpes Zoster (HZ) infection, which is associated with increased hospitalizations and healthcare resource utilization. Despite…
Abstract Number: 2676 • ACR Convergence 2024
Timeframe for Initiating Methotrexate and Vaccine Response Against Pneumococcus in Rheumatoid Arthritis: The VACIMRA Study
Jacques MOREL¹, Emmanuelle Dernis², christian roux³, Christophe Richez⁴, OLIVIER BROCQ⁵, Bruno Fautrel⁶, Carine SALLIOT⁷, Olivier Vittecoq⁸, Xavier Mariette⁹, Frédéric LIOTE¹⁰, Slim Lassoued¹¹, Cécile Gaujoux-Viala¹², Arnaud Constantin¹³, MArtin Soubrier¹⁴, Valerie Devauchelle¹⁵, Vincent Goeb¹⁶, Jacques-Eric Gottenberg¹⁷, Hubert Marotte¹⁸, Annouc Rémy Moulard¹, Corinne Merle de Boever¹, Héléna Huguet¹, Odile Launay¹⁹, Florence Galtier¹ and Marie Christine Picot¹, and F-CRIN networks iREIVAC and CRI-IMMIDIATE, ¹CHU and University of Montpellier, Montpellier, France, ²CH LE MANS, LE MANS, Pays de la Loire, France, ³rheumatology department, university Cote d'Azur, nice, France, ⁴Université de Bordeaux, Bordeaux, France, ⁵Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, ⁶INSERM, UMRS 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, and Sorbonne University – Assistance Publique-Hôpitaux de Paris, Département de Rhumatologie, Hôpital Pitié-Salpêtrière, Paris, Ile-de-France, France, ⁷CHU and University of Orléans, Orléans, France, ⁸CHU and University of Rouen, Rouen, France, ⁹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹⁰CHU and University of Paris Nord, Paris, France, ¹¹CH of Cahors, Cahors, France, ¹²CHU Nîmes, Nïmes, Languedoc-Roussillon, France, ¹³Hôpitaux de Toulouse, Toulouse, France, ¹⁴Gabriel-Montpied Hospital, Clermont-ferrand, France, ¹⁵UBO, Brest, France, ¹⁶CHu and University of Amiens, Ameins, France, ¹⁷Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ¹⁸Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM SAINBIOSE 1059, Saint-Etienne, France, ¹⁹Centre d’Investigation Clinique en Vaccinologie (CIC Cochin Pasteur), Hôpital Cochin, Paris, Ile-de-France, France
Background/Purpose: Pneumococcal vaccination is recommended for patients with chronic inflammatory rheumatism treated with immunosuppressants. Methotrexate (MTX) is the first-line treatment used in rheumatoid arthritis (RA),…
Abstract Number: 0239 • ACR Convergence 2024
Neutralising Antibody Responses to Bivalent SARS-CoV-2 Vaccines and Hybrid Immunity in Patients on TNF Inhibitors: A Prospective Cohort Study
Hilde S. Ørbo¹, Taissa M. Kasahara², Asia-Sophia Wolf³, Kristin H. Bjørlykke⁴, Joseph Sexton⁵, Ingrid Jyssum⁵, Anne Therese Tveter⁵, Guri Solum³, Ingrid Fadum Kjønstad³, Andreas Lind⁶, Veselka Petrova Dimova-Svetoslavova⁶, Tore K. Kvien⁷, Jørgen Jahnsen⁸, Espen A. Haavardsholm¹, Ludvig A. Munthe⁹, Sella A. Provan⁵, John Torgils Vaage⁹, Siri Mjaaland³, Kristin K. Jørgensen⁴, Gunnveig Grødeland⁹, Silje W. Syversen¹⁰ and Guro L. Goll¹⁰, ¹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ²University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ³Norwegian Institute of Public Health, Section for Immunology, Oslo, Norway, Oslo, Norway, ⁴Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, ⁵Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ⁶Oslo University Hospital, Department of Microbiology, Oslo, Norway, Oslo, Norway, ⁷Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁸Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, ⁹Oslo University Hospital, Department of Immunology, Oslo, Norway, and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, and University of Oslo (UiO), Institute of Health and Society, Oslo, Norway, Oslo, Norway
Background/Purpose: The SARS-CoV-2 virus mutates continuously, posing challenges for patients with immune-mediated inflammatory diseases (IMIDs) on tumour necrosis factor inhibitors (TNFi). These patients often have…
Abstract Number: 1302 • ACR Convergence 2024
Physician Knowledge, Attitudes and Perceived Barriers to Recommending the Recombinant Varicella Zoster Vaccine
cori sutton¹, yingxue wang² and priyanka iyer³, ¹UC Irvine, orange, ²UC Irvine, Orange, CA, ³Uc Irvine Medical center, orange
Background/Purpose: Varicella-zoster virus(VZV) or Shingles infections in immunocompromised individuals can lead to severe complications. Despite availability of the Recombinant Varicella Zoster vaccine(RZV), vaccination rates remain suboptimal. The…
Abstract Number: 0742 • ACR Convergence 2023
Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes
Natalie McCormick¹, Chio Yokose², Na Lu³ and Hyon K. Choi⁴, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴Massachusetts General Hospital and Harvard Medical School, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a revolutionary second-line treatment for type 2 diabetes associated with lower risk of cardiovascular and all-cause mortality, heart failure,…
Abstract Number: 1935 • ACR Convergence 2023
Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
Marion THOMAS¹, Maeva MASSON², Raphaele Seror³, Samuel Bitoun⁴, Henry DUPUY⁵, Lazato ESTIBALIZ⁵, Christophe Richez⁶, Yannick ALLANORE⁷ and Jerome AVOUAC⁸, ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²CHU Toulouse, Toulouse, France, ³University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁴CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, ⁵CHU Bordeaux, Bordeaux, France, ⁶Université de Bordeaux, Bordeaux, France, ⁷Université Paris Cité, Paris, France, ⁸Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…
Abstract Number: 0751 • ACR Convergence 2023
Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023
Sharon Abada¹, Jing Li¹, Gary Tarasovsky², Cherish Wilson³, Jinoos Yazdany¹, Mary Whooley¹ and Gabriela Schmajuk³, ¹University of California San Francisco, San Francisco, CA, ²San Francisco VA, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA
Background/Purpose: Patients receiving immunosuppressive therapies are known to have a higher risk of herpes zoster and subsequent complications compared to the general population. The recombinant…

« Previous Page
1
…
3
4
5
6
7
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].